We are pleased to be able to enter into a collaborative agreement with CGI which leverages the strengths of both companies. CGI is developing unique content in the areas of FISH and microarrays, while we offer unique manufacturing capabilities in both of these areas, said Dr. Carl Balezentis, President of Enzo Life Sciences. Specifically, this agreement enables us to offer our labeling products in conjunction with Cancer Genetics ™ FISH probes, which are highly regarded in the research market, and which also provide strong recognition for our technology. We also recognize that opportunities exist to expand our clinical lab offerings through the unique products and services for personalized cancer treatment being offered and being developed by CGI.

Dr. R.S.K. Chaganti, the founder and Chairman of CGI, said, This agreement will introduce the next generation of innovation and sensitivity in DNA probes being used for clinical cytogenetics for oncology.

SOURCE Enzo Biochem, Inc.